Endoscopic Ultrasound: Indian Perspective

Area of Science:

• Thoracic Surgery
• Pulmonary Medicine
• Oncology

Background:

• Mediastinoscopy has been the gold standard for lung cancer staging for over 30 years, offering visualization and tissue sampling of mediastinal nodes.
• Historically, it provided high sensitivity with low morbidity and mortality, crucial for accurate cancer diagnosis and treatment planning.

Discussion:

• Recent reports indicate decreased use of mediastinoscopy in community practice, with limited concomitant biopsy rates.
• Cervical mediastinoscopy has limitations, excluding key nodal stations like the pulmonary ligament and aortopulmonary window.
• The procedure requires general anesthesia, incurs significant costs (estimated $1,700-$7,500), and has a 1% morbidity and 0.2% mortality rate.

Key Insights:

• Mediastinoscopy's limitations in accessibility and cost have led to its reduced utilization.
• The procedure's inability to access all relevant nodal stations presents a diagnostic challenge.
• The financial burden associated with mediastinoscopy further complicates its application in routine patient care.

Outlook:

• The limitations of mediastinoscopy have driven the development of newer diagnostic technologies.
• Endobronchial ultrasound (EBUS) emerged in the 1990s as a potential alternative, addressing some of mediastinoscopy's shortcomings.
• Future research will likely focus on the comparative efficacy and cost-effectiveness of EBUS versus traditional mediastinoscopy for lung cancer staging.